https://openbell.ai/ 2026-11-03T08:34:02.117Z hourly 1.0 https://openbell.ai/support 2026-11-03T08:34:02.117Z monthly 0.7 https://openbell.ai/privacy 2026-11-03T08:34:02.117Z monthly 0.5 https://openbell.ai/terms 2026-11-03T08:34:02.117Z monthly 0.5 https://openbell.ai/feed.json 2026-11-03T08:34:02.117Z hourly 0.8 https://openbell.ai/news/RBI:1793694730000 2026-11-03T08:32:10.000Z daily 0.9 https://cdn.brandfetch.io/RBI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Raiffeisen Bank International Reports Nine-Month Profit Growth and Acquisition Completion Raiffeisen Bank International reported a 10% increase in profit for the first nine months of the year, to €1.1 billion. The bank also confirmed it completed its acquisition of Romania’s Garanti Bank. The company disclosed both developments on November 3, 2026. https://openbell.ai/news/LHA:1793694718000 2026-11-03T08:31:58.000Z daily 0.9 https://cdn.brandfetch.io/LHA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Lufthansa Reports Q3 2026 Results and Lowers Full-Year Operating Profit Outlook Deutsche Lufthansa reported third-quarter 2026 adjusted EBIT of €1.41 billion, up 6% year over year and above analysts’ €1.37 billion estimate. Revenue increased 9% to €12.24 billion, and net profit rose 30% to €1.26 billion, supported by cargo and maintenance demand and cost discipline. The airline lowered its full-year adjusted EBIT outlook to €1.7 billion–€2.0 billion from a previous upper limit of €2.2 billion, citing higher fuel costs and the late stage of the fiscal year; it said the revised range is in line with market expectations. https://openbell.ai/news/EVK:1793694716000 2026-11-03T08:31:56.000Z daily 0.9 https://cdn.brandfetch.io/EVK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Evonik Reports Q3 2026 Results and Increases Full-Year Outlook Evonik Industries reported Q3 2026 adjusted EBITDA of €629 million, up 40% from €509 million a year earlier, supported by higher prices and sales volumes. It posted a net loss of €53 million, mainly due to a €313 million provision for additional efficiency-program measures. Management reaffirmed Evonik’s independence and rejected potential takeover interest from BASF, saying restructuring is expected to make its portfolio more attractive. https://openbell.ai/news/FMS:1793694705000 2026-11-03T08:31:45.000Z daily 0.9 https://cdn.brandfetch.io/FMS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Fresenius Medical Care Narrows 2026 Earnings Outlook Fresenius Medical Care narrowed its 2026 operating income outlook to a range from flat to a mid-single-digit percentage decline, versus its previous guidance of a mid-single-digit percentage change around the prior year’s level. The company cited operating results in the first nine months and expected fourth-quarter headwinds. It maintained its revenue outlook at approximately the prior year’s level. https://openbell.ai/news/VSURE:1793694698000 2026-11-03T08:31:38.000Z daily 0.9 https://cdn.brandfetch.io/VSURE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Verisure Reports Third Quarter 2026 Financial Results Verisure reported third-quarter 2026 revenue of 1,030.8 million, up 10.5% from 933.0 million in the prior period. Adjusted EBITDA increased to 488.6 million from 442.6 million, and Adjusted EBIT rose to 285.1 million from 250.3 million. Management said the company remains focused on prioritizing quality growth. https://openbell.ai/news/BOSS:1793694697000 2026-11-03T08:31:37.000Z daily 0.9 https://cdn.brandfetch.io/BOSS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Hugo Boss Issues Revenue Warning for 2026 Hugo Boss lowered its 2026 revenue outlook, now forecasting a high-single-digit percentage decline on a currency-adjusted basis, compared with its previous forecast of a mid-to-high-single-digit decline. The company also reported lower sales and profit in the preceding quarter. The revised guidance reflects a weaker outlook for the rest of the year. https://openbell.ai/news/BAYN:1793694697000 2026-11-03T08:31:37.000Z daily 0.9 https://cdn.brandfetch.io/BAYN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bayer Reports Unexpected Q3 Earnings Growth Driven by Pharmaceuticals Bayer AG reported an unexpected increase in third-quarter operating results, driven by a recovery and strong growth in its Pharmaceuticals division. CEO Bill Anderson said the division had reached a turning point, and Bayer raised its full-year 2026 pharmaceutical margin expectations. Pharma’s performance helped offset ongoing market pressures in the agricultural and consumer-health divisions. https://openbell.ai/news/BIM:1793694697000 2026-11-03T08:31:37.000Z daily 0.9 https://cdn.brandfetch.io/BIM/w/400/h/400?c=1idopYfmtR7ZKg8QMud bioMérieux Reports Q3 2026 Revenue Exceeding Analyst Expectations bioMérieux reported Q3 2026 revenue of €1.04 billion, up 9.9% year over year on a reported basis and 8.1% organically, exceeding analyst expectations of €1.01 billion and 5.9% organic growth. The company confirmed its 2026 objectives of 3% to 5% organic revenue growth and contributive operating income that is stable or increases by up to 10% organically. https://openbell.ai/news/LECN:1793693057000 2026-11-03T08:04:17.000Z daily 0.9 https://cdn.brandfetch.io/LECN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Leclanché CEO States Need for 50 Million in Funding Leclanché SA’s CEO said the company needs to raise 50 million to fund ongoing operations and strategic progress. The report did not specify the currency, financing method, or any stock-market impact. https://openbell.ai/news/BIG:1793693026000 2026-11-03T08:03:46.000Z daily 0.9 https://cdn.brandfetch.io/BIG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bigben Interactive Convenes Shareholders and Creditors for Accelerated Safeguard Plan Vote Bigben Interactive has begun the process of seeking shareholder and creditor votes on its accelerated safeguard plan after an August 17, 2026 judgment by the Commercial Court of Lille Métropole. The court is scheduled to rule on the plan’s adoption on December 9, 2026. If adopted, financial restructuring transactions are expected to be implemented and completed by the end of the first quarter of 2027; the company said it will provide further details on the timetable for capital transactions. https://openbell.ai/news/IMMNOV:1793693017000 2026-11-03T08:03:37.000Z daily 0.9 https://cdn.brandfetch.io/IMMNOV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Immunovia AB Releases Q3 2026 Interim Report Immunovia reported Q3 2026 net sales of SEK 843,000 and an operating loss of SEK 17.7 million, down from SEK 25.1 million a year earlier. Operating cash flow improved to negative SEK 14.9 million from negative SEK 16.1 million, partly due to lower clinical-study spending. PancreaSure was being used at 36 surveillance centers, and the company submitted a Medicare coverage request on September 28. Immunovia also announced a rights issue of approximately SEK 63 million, about 80% of which was secured. https://openbell.ai/news/NACON:1793693013000 2026-11-03T08:03:33.000Z daily 0.9 https://cdn.brandfetch.io/NACON/w/400/h/400?c=1idopYfmtR7ZKg8QMud Nacon Convenes Shareholders and Creditors to Vote on Reorganisation Plan Nacon has called shareholders and creditor classes to vote on a draft reorganisation plan after the Lille Métropole Commercial Court opened judicial reorganisation proceedings on March 2, 2026. The plan proposes operational and workforce restructuring, debt and liability restructuring, an equity injection with subscription rights preserved, and conversion of intragroup receivables into equity, aiming to support long-term viability and protect jobs. The Court is scheduled to rule on the plan on December 9, 2026, with the financial restructuring expected to conclude by the end of Q1 2027. https://openbell.ai/news/LEVEL:1793693011000 2026-11-03T08:03:31.000Z daily 0.9 https://cdn.brandfetch.io/LEVEL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Nordic LEVEL Group Reports Q3 2026 Financial Results Nordic LEVEL Group AB reported Q3 2026 revenue growth of 28.6% year over year and returned to EBITDA profitability. Record order intake and a strong backlog supported the quarter, while year-to-date revenue and earnings remained weaker. Management cited robust data-center demand and new long-term targets as priorities for its forward-looking strategy. https://openbell.ai/news/LLYC:1793692976000 2026-11-03T08:02:56.000Z daily 0.9 https://cdn.brandfetch.io/LLYC/w/400/h/400?c=1idopYfmtR7ZKg8QMud LLYC Updates Full-Year 2026 Guidance Following H1 Results LLYC reported first-half 2026 total income of €53.6 million and recurring EBITDA of €5.3 million during a transition in its business model. The company revised its full-year guidance to operating revenue of €81 million to €82.5 million and recurring EBITDA of €15.5 million. Management said the forecast reflects the near-completion of its efficiency plan, which is intended to support its strategic transition. https://openbell.ai/news/DVYSR:1793692963000 2026-11-03T08:02:43.000Z daily 0.9 https://cdn.brandfetch.io/DVYSR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Devyser Diagnostics AB Reports Q3 2026 Interim Results Devyser Diagnostics AB reported a 5.8% year-over-year sales increase for July–September 2026 and EBIT of SEK 7.1 million. Gross margin improved to 83.0%. The company said direct-market demand remains strong, but a distributor’s inventory correction is expected to weigh on sales through Q4 2026, with conditions expected to normalize in 2027. https://openbell.ai/news/O4B:1793692957000 2026-11-03T08:02:37.000Z daily 0.9 https://cdn.brandfetch.io/O4B/w/400/h/400?c=1idopYfmtR7ZKg8QMud OVB Holding AG Reports Nine-Month 2026 Financial Results and Raises Guidance OVB Holding AG reported brokerage income of €361.4 million for the first nine months of 2026, up 11.8% year over year. EBIT increased 83.3% to €11.4 million, while earnings per share reached €0.73. The company raised its full-year brokerage income guidance to €450 million–€490 million and kept its EBIT guidance unchanged at €10 million–€15 million. https://openbell.ai/news/PLT:1793692942000 2026-11-03T08:02:22.000Z daily 0.9 https://cdn.brandfetch.io/PLT/w/400/h/400?c=1idopYfmtR7ZKg8QMud poLight ASA Receives Follow-on Mass Production Purchase Order for AR/MR Application poLight ASA received a follow-on mass-production purchase order worth approximately NOK 0.75 million for its TLens® technology, for a consumer OEM’s AR/MR application. The project was originally defined as a design-in on July 10, 2026, and delivery is expected in the first quarter of 2027. CEO Dr. Øyvind Isaksen said the order indicates that a market release and design-win may be approaching. https://openbell.ai/news/ITAB:1793692942000 2026-11-03T08:02:22.000Z daily 0.9 https://cdn.brandfetch.io/ITAB/w/400/h/400?c=1idopYfmtR7ZKg8QMud ITAB Group Reports Q3 2026 Results with Significant One-Off Costs ITAB Group’s Q3 2026 net sales rose 3.0% year over year to SEK 3,397 million, while operating profit fell to SEK 6 million from SEK 220 million, for a 0.2% operating margin. The quarter included SEK 242 million in one-off costs, including SEK 222 million related to discontinuing the group-wide ERP implementation; net income was negative SEK 68 million and earnings per share were negative SEK 0.29. CEO Björn Borgman said HMY acquisition synergies are progressing as planned, while the company continues to streamline production and improve efficiency to pursue its 7–9% EBIT margin target. https://openbell.ai/news/WSU:1793692921000 2026-11-03T08:02:01.000Z daily 0.9 https://cdn.brandfetch.io/WSU/w/400/h/400?c=1idopYfmtR7ZKg8QMud WashTec AG Reports Q3 2026 Financial Results WashTec AG reported revenue of €374.5 million, up 4.6% from €358.2 million a year earlier. EBIT declined 20.7% to €25.7 million, with the margin falling to 6.9% from 9.0%, while free cash flow dropped 69.1% to €8.6 million. The company attributed weaker profitability to delays in efficiency programs and one-off organizational optimization costs. WashTec maintained its 2026 guidance for mid-single-digit revenue growth and an EBIT margin of 8% to 9%. https://openbell.ai/news/BSLN:1793692921000 2026-11-03T08:02:01.000Z daily 0.9 https://cdn.brandfetch.io/BSLN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Basilea Receives USD 37.5 Million Milestone Payment for Cresemba Sales Basilea Pharmaceutica said strong European sales of its antifungal drug Cresemba triggered a USD 37.5 million milestone payment from license partner Pfizer. Cresemba’s global in-market sales totaled USD 817 million in the 12 months ending June 2026, making it the largest branded antifungal for invasive fungal infections, according to the company. Basilea said it will continue focusing on patient outcomes with Cresemba and developing its broader R&D portfolio. https://openbell.ai/news/OKEA:1793692919000 2026-11-03T08:01:59.000Z daily 0.9 https://cdn.brandfetch.io/OKEA/w/400/h/400?c=1idopYfmtR7ZKg8QMud OKEA ASA Reports Q3 2026 Results, Updates Guidance and Resumes Dividends OKEA ASA reported a net profit of USD 29 million for Q3 2026 and total cash of USD 476 million. Citing improved production and operational efficiency, it raised and narrowed its 2026 production guidance to 31–32 kboepd. The company plans to resume quarterly dividends, with NOK 2.00 per share scheduled for December, and said development of the Bestla field is ahead of its original schedule. https://openbell.ai/news/BMAG:1793692918000 2026-11-03T08:01:58.000Z daily 0.9 https://cdn.brandfetch.io/BMAG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bajaj Mobility AG Reports Q3 2026 Financial Results Bajaj Mobility AG reported Q3 2026 revenue of EUR 351.1 million, up 57.0% year over year, and nine-month revenue of EUR 1,052.5 million. Third-quarter EBIT was EUR 11.3 million, EUR 10 million higher than in Q2. Motorcycle sales rose 51.1% to 47,390 units, while motorcycle revenue increased 84.0% to EUR 288.3 million. The company said its KTM, Husqvarna and GASGAS brands supported performance and that it reduced overhead costs by EUR 96.9 million in the first nine months. https://openbell.ai/news/TMV:1793692915000 2026-11-03T08:01:55.000Z daily 0.9 https://cdn.brandfetch.io/TMV/w/400/h/400?c=1idopYfmtR7ZKg8QMud TeamViewer Reports Q3 2026 Results and Adjusts Full-Year Revenue Guidance TeamViewer reported Q3 2026 revenue of €184.5 million, down 2.2% year over year in constant currencies, and an Adjusted EBITDA margin of 42.8%. It cited delayed conversion of large enterprise deals and economic uncertainty in Europe, despite momentum in TeamViewer ONE and DEX and a stabilizing SMB business. The company cut its 2026 revenue growth guidance to -2% to -1% from 0% to 3%, while reaffirming its approximately 43% Adjusted EBITDA margin outlook and expecting faster ARR growth in 2027. https://openbell.ai/news/BCHN:1793692913000 2026-11-03T08:01:53.000Z daily 0.9 https://cdn.brandfetch.io/BCHN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Burckhardt Compression Reports Strong Order Intake for First Half of 2026/27 Burckhardt Compression reported first-half 2026/27 order intake of CHF 422.5 million, up 5% from the same period a year earlier. Management described the result as a significant surprise and reaffirmed its financial targets for the full fiscal year. https://openbell.ai/news/RAY.B:1793692912000 2026-11-03T08:01:52.000Z daily 0.9 https://cdn.brandfetch.io/RAY.B/w/400/h/400?c=1idopYfmtR7ZKg8QMud RaySearch Laboratories Reports Record Q3 2026 Sales RaySearch Laboratories reported record Q3 2026 sales of SEK 394 million, up 19% year over year, while order intake increased 30%, driven largely by strong U.S. demand. A shift in hardware mix and higher operating costs pressured profit margins. Management reaffirmed its full-year 2026 target of an operating margin of at least 25%. No stock-price movement was reported. https://openbell.ai/news/CASH:1793692911000 2026-11-03T08:01:51.000Z daily 0.9 https://cdn.brandfetch.io/CASH/w/400/h/400?c=1idopYfmtR7ZKg8QMud Prosegur Cash Reports Q3 2026 Financial Results Prosegur Cash said sales growth accelerated to 5.3% in Q3 2026, bringing sales growth for the first nine months to 1.4%. Transformation products grew 8.3% excluding AVOS. The company also reported higher net income and free cash flow, while total net debt fell by €53 million over the past 12 months. https://openbell.ai/news/NORBT:1793692908000 2026-11-03T08:01:48.000Z daily 0.9 https://cdn.brandfetch.io/NORBT/w/400/h/400?c=1idopYfmtR7ZKg8QMud NORBIT Receives NOK 185 Million Contract Manufacturing Order NORBIT ASA’s Product Innovation & Realization segment received a contract manufacturing order worth approximately NOK 185 million from an undisclosed European defense and security client. Most deliveries are scheduled for the first quarter of 2027, alongside previously awarded orders of approximately NOK 100 million for the same period. CEO Per Jørgen Weisethaunet cited strong demand for European-made defense technology and NORBIT’s role as an industrial scaling partner. https://openbell.ai/news/NCC.B:1793692905000 2026-11-03T08:01:45.000Z daily 0.9 https://cdn.brandfetch.io/NCC.B/w/400/h/400?c=1idopYfmtR7ZKg8QMud NCC Reports Q3 2026 Results and Provides Update on Industry Division Sale NCC reported improved adjusted operating profit in Q3 2026 across continuing and discontinued operations, with contracting margins of 3.5%. Order intake increased for the fourth consecutive quarter. The company also updated plans to sell its Industry division at an enterprise value of SEK 8.2 billion, with the transaction expected to close in the second half of 2027.